StockDrifts LogoStockDrifts

MedPacto 235980

Company
메드팩토MedPacto
Insiders
1
Buys
1
Total Value
₩116M ($80K)
Avg Return
+60.11%
Last Filing
2025-03-06

MedPacto (235980) has 1 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩116M ($80K) in reported transaction value. The earliest filing StockDrifts holds for MedPacto is dated 2025-03-05; the most recent is 2025-03-06. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +60.11%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-03-06BUYPROGRAM
우정원
Woojeongwon
president15.0K₩3,635+60.1%₩55M ($38K)
2025-03-06BUYPROGRAM
김성진
Seongjin Kim
CEO31.9K₩3,635+60.1%₩116M ($80K)
2025-03-06BUYPROGRAM
이지훈
Jihoon Lee
Managing Director7.0K₩3,635+60.1%₩25M ($18K)
2025-03-05BUYPROGRAM
양경민
Kyungmin Yang
Managing Director10.0K₩3,405+70.9%₩34M ($24K)
2025-03-05BUYPROGRAM
장민후
Jang Min-hoo
Managing Director10.5K₩3,405+70.9%₩36M ($25K)
2025-03-05BUYPROGRAM
허민규
Heo Min-gyu
Managing Director10.0K₩3,405+70.9%₩34M ($24K)
2025-03-05BUYPROGRAM
우정원
Woojeongwon
president15.0K₩3,405+70.9%₩51M ($35K)

Frequently asked questions

Who has been buying MedPacto stock?
1 distinct insiders have filed 1 disclosed insider purchases in MedPacto (235980), most recently on 2025-03-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does MedPacto have?
MedPacto has 1 buy-side and 0 sell-side disclosures on record, covering ₩116M ($80K) in total reported value, spanning 2025-03-05 to 2025-03-06.
Where does StockDrifts get MedPacto insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for MedPacto. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.